Novocure has received FDA clearance for its next-generation head flexible electrode (HFE) transducer arrays designed for use with Optune Gio, a wearable device indicated for the treatment of glioblastoma in adults. The updated HFEs are engineered to improve patient comfort during the administration of Tumor Treating Fields (TTFields).
Enhanced Comfort and Design
The newly approved HFE arrays are lighter and thinner, offering a more comfortable experience for patients undergoing treatment. Mukund Paravasthu, Novocure’s chief operating officer, emphasized the company's commitment to product innovation that prioritizes patient needs. Novocure plans a controlled transition to the new arrays for existing Optune Gio users in the United States throughout the first half of 2025.
Mechanism of Action
Optune Gio works by delivering TTFields, alternating electric fields that exert physical forces on electrically charged components within dividing cancer cells, thereby inhibiting their growth. The device is intended for use in conjunction with temozolomide (TMZ) chemotherapy for glioblastoma patients.
Novocure's Expanding Portfolio
This approval follows the recent FDA clearance of Optune Lua, another TTField-emitting wearable from Novocure, indicated for metastatic non-small cell lung cancer (mNSCLC). As of Q3 2024, over 4,000 patients are using Novocure's TTFields therapy. The company's Q3 2024 financials reported revenues of $155 million, a 22% year-over-year increase.
